NDC 0024-5862

Mozobil

Plerixafor

Mozobil is a Subcutaneous Solution in the Human Prescription Drug category. It is labeled and distributed by Sanofi-aventis U.s. Llc. The primary component is Plerixafor.

• Product ID: 0024-5862_37a4b719-07f1-4d12-a2f8-ce3ba83e14c4
• NDC: 0024-5862
• Product Type: Human Prescription Drug
• Proprietary Name: Mozobil
• Generic Name: Plerixafor
• Dosage Form: Solution
• Route of Administration: SUBCUTANEOUS
• Marketing Start Date: 2013-09-01
• Marketing Category: NDA / NDA
• Application Number: NDA022311
• Labeler Name: sanofi-aventis U.S. LLC
• Substance Name: PLERIXAFOR
• Active Ingredient Strength: 24 mg/1.2mL
• Pharm Classes: Hematopoietic Stem Cell Mobilizer [EPC],Increased Hematopoietic Stem Cell Mobilization [PE]
• NDC Exclude Flag: N
• Listing Certified Through: 2020-12-31

Packaging

NDC 0024-5862-01

1 VIAL, SINGLE-USE in 1 CARTON (0024-5862-01) > 1.2 mL in 1 VIAL, SINGLE-USE

• Marketing Start Date: 2013-09-01
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0024-5862-01 [00024586201]

Mozobil SOLUTION

• Marketing Category: NDA
• Application Number: NDA022311
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2013-09-01

Drug Details

Active Ingredients

Ingredient	Strength
PLERIXAFOR	24 mg/1.2mL

OpenFDA Data

• SPL SET ID: 0ed08d2b-5051-46b2-aa37-1d6275bf9003
• Manufacturer:
  • sanofi-aventis U.S. LLC
• UNII:
  • S915P5499N
• RxNorm Concept Unique ID - RxCUI:
  • 828703
  • 828700

Pharmacological Class

• Hematopoietic Stem Cell Mobilizer [EPC]
• Increased Hematopoietic Stem Cell Mobilization [PE]